Jasper Therapeutics (NASDAQ:JSPR) Announces Quarterly Earnings Results

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) posted its earnings results on Monday. The company reported ($10.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.77) by ($8.42), FiscalAI reports. The business had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $6.00 million.

Jasper Therapeutics Trading Down 14.0%

Shares of NASDAQ:JSPR opened at $11.77 on Tuesday. The stock has a fifty day simple moving average of $16.60 and a two-hundred day simple moving average of $23.97. Jasper Therapeutics has a 12-month low of $9.45 and a 12-month high of $72.60. The stock has a market capitalization of $13.06 million, a price-to-earnings ratio of -0.25 and a beta of 3.30.

Analyst Ratings Changes

Several research analysts have recently issued reports on JSPR shares. William Blair started coverage on Jasper Therapeutics in a research report on Wednesday, October 14th. They issued an “outperform” rating for the company. Piper Sandler assumed coverage on Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $60.00 price target on the stock. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Finally, Wall Street Zen downgraded Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $220.00.

Get Our Latest Analysis on Jasper Therapeutics

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for conditions involving blood-forming stem cells and mast cells. Its research focuses on c-Kit, also known as CD117, a protein found on these cells. The company’s lead investigational drug, briquilimab (formerly JSP191), is a monoclonal antibody that targets c-Kit. Jasper has studied briquilimab as a conditioning treatment for stem cell transplantation and gene therapy, and is evaluating it for mast cell-mediated diseases, including chronic spontaneous urticaria.

Read More

Earnings History for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.